Skip to content
Gene2Rx home

Try

Loading…

Search couldn't load. Check your connection and try again, or use the medication lookup.

No pages match .

The medication lookup checks any medication by name, including ones without their own page.

Get my report
In the Full Report

Siponimod

Immunosuppressants (Sphingosine-1-Phosphate Receptor Modulator)

Siponimod (Mayzent) is a daily tablet for relapsing forms of multiple sclerosis in adults. About 80% of it is broken down by CYP2C9, so people with reduced-function CYP2C9 variants are exposed to much more of the drug. It is one of the few medicines whose label requires a genetic test before the first dose: the maintenance dose is set by CYP2C9 genotype, and siponimod must not be used in people with the *3/*3 genotype [1]. The label's categories are specific genotypes, not metabolizer groups, so the diplotype in a result matters more than the phenotype label.

At a glance
Brand namesMayzent
Used forRelapsing forms of multiple sclerosis in adults: clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease
GenesCYP2C9
GuidanceFDA label (Sections 2.1 to 2.3, 4, 8.6 and 12.5): genotype testing required before starting; no CPIC guideline

How siponimod works

Siponimod is a sphingosine 1-phosphate (S1P) receptor modulator. It binds S1P receptors 1 and 5 and stops lymphocytes, a type of white blood cell, from leaving the lymph nodes, so fewer of them circulate. How this helps in multiple sclerosis is not known for certain, but it may reduce the number of lymphocytes that reach the brain and spinal cord. In a typical patient the lymphocyte count falls to about 20 to 30% of its starting level [1].

The first doses also slow the heart rate and can delay electrical conduction in the heart for a short time. For that reason treatment starts with a few days of small, rising doses before the maintenance dose, and the label asks for an ECG before starting, along with a blood count, liver tests and an eye examination [1].

CYP2C9 accounts for about 80% of siponimod metabolism in people with two normal-function copies, and CYP3A4 for about 6%. The half-life is about 30 hours. The main metabolites are not expected to contribute to the drug's effect, so slower CYP2C9 activity means more active drug for longer [1].

How CYP2C9 affects siponimod

CYP2C9 variants are named as star alleles. *1 is the reference version with normal function. The two common reduced-function alleles are *2, which CPIC classes as decreased function, and *3, which it classes as no function [2]. Everyone carries two copies, so a result is written as a pair (a diplotype), such as *1/*3.

The label gives measured exposure for each of the common genotypes. Compared with *1/*1, total exposure (area under the curve) was about 25% higher with *2/*2, 61% higher with *1/*3, 91% higher with *2/*3 and 285% higher with *3/*3. The half-life stretched to about 51 hours with *2/*3 and 126 hours with *3/*3. *1/*2 clears siponimod about as fast as *1/*1, so similar exposure is expected [1].

According to the label, the *3/*3 genotype occurs in about 0.5% of white patients and 1% of Asian patients and is less common in other groups; *1/*3 or *2/*3 occurs in 2 to 20% of people, depending on ancestry. Other alleles such as *5, *6, *8 and *11 also reduce or remove CYP2C9 function and are more common in people of African ancestry. Their effect on siponimod has not been studied, though the label expects loss-of-function alleles such as *6 to act like *3 [1].

Why the metabolizer label is not enough

Gene2Rx, like most laboratories, also turns the diplotype into a metabolizer group using CPIC's activity scores [2]. Those groups do not line up with the label's dosing categories:

  • An intermediate metabolizer can be *1/*2 or *2/*2 (2 mg maintenance on the label) or *1/*3 (1 mg).
  • A poor metabolizer can be *2/*3 (1 mg) or *3/*3 (contraindicated).
  • Diplotypes with rarer alleles such as *1/*8 or *3/*6 have no category on the label at all.

So the diplotype printed in your report, not the word "intermediate" or "poor", is what maps onto the label.

What the guidelines recommend

The FDA-approved label is the main guidance. Before the first dose it says to test patients for CYP2C9 variants to determine genotype, and notes that no FDA-cleared or approved test for directing siponimod use is currently available [1]. The FDA lists siponimod and CYP2C9 in Section 1 of its Table of Pharmacogenetic Associations [3]. CPIC has given the CYP2C9 and siponimod pair a provisional level A, but has not published a siponimod guideline [4].

Mayzent label dosing by CYP2C9 genotype
GenotypeExposure vs *1/*1Label recommendation
*1/*1, *1/*2Similar5-day titration, then 2 mg once daily
*2/*2About 25% higher5-day titration, then 2 mg once daily
*1/*3, *2/*3About 61% and 91% higher4-day titration, then 1 mg once daily
*3/*3About 285% higherContraindicated: do not use

The Gene2Rx report gives the FDA's wording for each metabolizer group:

CYP2C9 results and siponimod in the Gene2Rx report (FDA)
ResultWhat it meansGuideline recommendation
Normal Metabolizer Usual siponimod exposure (*1/*1). No genotype-based change; label dosing of 2 mg maintenance applies.
Intermediate Metabolizer Results in higher systemic concentrations. Adjust the dosage based on genotype as the label directs. In practice: *1/*3 takes 1 mg; *1/*2 and *2/*2 keep 2 mg.
Poor Metabolizer Results in higher systemic concentrations. Do not use with the *3/*3 genotype. For other poor metabolizer genotypes, adjust the dosage as the label directs (for *2/*3, 1 mg).
Indeterminate or not available The alleles found could not be assigned a function, or the gene could not be called. No genotype-based advice from this result; the label still requires genotyping before treatment.

The report describes the dosing guidance for intermediate metabolizers as "alternate dosing" and for poor metabolizers as "alternate drug". The second applies in full only to *3/*3.

Want to know what your genetics say about how you'll respond to Siponimod?

A Gene2Rx report reads your own DNA to show how it may affect your response to Siponimod and your other medications.

Using your result

If siponimod is being considered, your neurologist will order CYP2C9 genotyping before the first dose, because the label requires it. A clinical laboratory test is the appropriate basis for that decision. A Gene2Rx result can tell you in advance what to expect and can be shared with the prescriber, but it should not replace the clinical test. Do not start, stop or change a medicine on the strength of a genetic result without your prescriber. The label also warns that multiple sclerosis can, rarely, worsen sharply after an S1P receptor modulator is stopped [1].

Other medicines can change siponimod exposure as much as genotype does. Fluconazole, a moderate inhibitor of both CYP2C9 and CYP3A4, doubled siponimod exposure in people with *1/*1. The label advises against combining siponimod with strong CYP2C9 inhibitors and calls for monitoring with moderate ones. In the other direction, rifampin cut exposure by 57%, and dual moderate CYP2C9 and strong CYP3A4 inducers are not recommended with any genotype. In people with *1/*3 or *2/*3 the label also asks prescribers to watch for loss of effect with moderate or strong CYP3A4 inducers [1].

The label lists other checks that have nothing to do with genetics: heart conditions and medicines that slow the heart rate, a recent blood count, liver tests, an eye examination for macular edema, and pregnancy, since the drug can harm a fetus [1].

What this result cannot tell you

Gene2Rx reads the variant calls in the file you upload. Consumer arrays from 23andMe, AncestryDNA and MyHeritage are not clinical-grade tests, and their raw data is labeled not for medical use. Arrays read fixed positions, and processing uses imputation to infer some variants that were not measured. A normal result means none of the assessed CYP2C9 variants was found among the positions your data covers or imputation inferred; it cannot rule out a rare variant elsewhere. For a drug with a contraindicated genotype and a label that requires testing, that is a real limit, and it is why the clinical test comes first.

The label's dosing covers *1, *2 and *3 only. If your diplotype includes a rarer reduced-function allele, the label gives no specific dose, and the decision rests with your neurologist. If a clinical laboratory has already reported your CYP2C9 genotype, those results can be entered for a Panel Report.

Common questions

Can I use my Gene2Rx result instead of the required CYP2C9 test?

It should not replace it. The label requires genotyping before treatment, and a consumer array is not a clinical test. Your result can be shared with your neurologist as background.

My report says poor metabolizer. Can I take siponimod?

It depends on the diplotype. *3/*3 is contraindicated; *2/*3 is given at 1 mg (see What the guidelines recommend).

My report says intermediate metabolizer. Do I need the lower dose?

Only for *1/*3 on the label. *1/*2 and *2/*2 keep the 2 mg dose.

Sources and further reading

  1. Mayzent (siponimod) tablets, prescribing information. Novartis. DailyMed. Indication, pre-treatment genotyping (2.1), dosing by genotype (2.2, 2.3), contraindications (4), interactions (7.5, 7.6), CYP2C9 genotype (8.6), pharmacokinetics and pharmacogenomics (12.3, 12.5).
  2. Karnes JH et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther (2021). The CYP2C9 activity score system used to assign metabolizer groups.
  3. FDA. Table of Pharmacogenetic Associations. Siponimod with CYP2C9 in Section 1.
  4. CPIC. Gene-drug pairs and CPIC levels (spreadsheet). CYP2C9 and siponimod: provisional level A, no guideline.
Disclaimer: This document is for informational purposes only and is not a substitute for medical advice. Clinical decisions should be made by a qualified healthcare professional.

Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.

I'm Interested